Moderna (MRNA) Interest & Investment Income (2018 - 2026)

Moderna (MRNA) has reported Interest & Investment Income for 9 consecutive years, with $67.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Interest & Investment Income fell 17.28% year-over-year to $67.0 million in Q2 2026; TTM through Jun 2026 was $282.0 million, a 22.74% decrease from a year earlier, with the FY2025 full-year figure at $314.0 million, down 26.12% from the prior year.
• Interest & Investment Income was $67.0 million for Q2 2026 at Moderna, down from $72.0 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $120.0 million in Q1 2024 and troughed at $15.0 million in Q1 2022.
• A 5-year average of $83.3 million and a median of $88.5 million in 2022 frame the typical range for Interest & Investment Income.
• Across the five-year window, Interest & Investment Income surged 1350.0% in 2022 and dropped 29.13% in 2025, its largest moves.
• Over 5 years, Interest & Investment Income stood at $87.0 million in 2022, then gained by 18.39% to $103.0 million in 2023, then slipped by 11.65% to $91.0 million in 2024, then declined by 23.08% to $70.0 million in 2025, then retreated by 4.29% to $67.0 million in 2026.
• The last three Interest & Investment Income figures came in at $67.0 million (Q2 2026), $72.0 million (Q1 2026), and $70.0 million (Q4 2025), per Business Quant data.